Project Grant R01CA289291
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$512K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $400,890 from March 1, 2025 to February 28, 2028 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The goal is to utilize patient-derived colorectal cancer organoids in a pathomimetic chip model to profile tumor-microbiome interactions and elucidate how the gut microbiome may modulate immune checkpoint molecules, with the aim of enhancing immunotherapy...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The objective is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can establish multiple levels of hypoxia, investigate spatiotemporal interactions between the tumor microenvironment and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,475 to The University of Texas Southwestern Medical Center to develop an in vitro cancer metastasis model system using decellularized tissue "biomatrices" that can recapitulate organ-specific metastasis. The researchers aim to generate a comprehensive panel of biomatrices representing common metastatic sites, validate the model's ability to reflect organ-specificity of...
This three-year, $681,444 National Science Foundation project grant supports collaborative research to develop tumor-mimetic collagen hydrogels for testing the role of structural cues on cancer cell migration. The Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded the funding under the Engineering program (CFDA 47.041), which aims to foster innovation and excellence in engineering research. The Rochester Institute of Technology will receive the award to create a...
The National Cancer Institute awarded a $648,846 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Washington University in St. Louis. The 5-year grant, effective July 1, 2024, will support research to understand how stromal senescence impacts the tumor microenvironment and immune responses in pancreatic ductal adenocarcinoma. Key objectives include evaluating how extracellular matrix biophysical properties regulate senescent cancer-associated fibroblasts, assessing...
This $627,422 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a first-of-its-kind intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The award to the Regents of the University of Michigan will fund research to engineer commensal E. coli bacteria to display the anti-toxin enzyme ColBs, which can neutralize the colibactin genotoxin and prevent associated DNA damage and tumorigenesis. Key...
This $811,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will fund the development of a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis with an agent-based modeling framework (PhysiCell) to simulate cell movement and interactions in virtual tissue environments. This will be...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $222,027 to the University of Pittsburgh to develop a novel computational imaging algorithm for quantitatively characterizing the mechanobiological properties of 3D tumor microenvironments. The algorithm will combine high-resolution digital pathology imaging and highly multiplexed immunofluorescence microscopy with physical optics-based principles to capture structural and...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at investigating the role and therapeutic targeting of the G protein-coupled receptor GPR56 in colorectal cancer. The key objectives of this $406,611 award, with a project period from April 1, 2025 to March 31, 2030, are to: 1) characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is focused on the functional and molecular characterization of oncofetal stem cells in colorectal cancer (CRC). The $560,297 grant, awarded on September 1, 2024, will fund a 5-year research project conducted by the Icahn School of Medicine at Mount Sinai. The key products and services to be delivered under this award include: 1) Generating phenotypic transcriptional reporters to track...